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disabilities. Although the Advisory Committee on Immunization
Practices has recommended meningococcal vaccination for at-risk
children aged 9 through 23 months, it has not endorsed universal
vaccination. Health insurance payments for the vaccination of chil-
dren who are not at risk are likely to be limited. Use of infant
meningococcal vaccines by these families will thus depend on the
preferences of physicians who might recommend vaccination to
parents, as well as parents’ preferences. Objective: To quantify
pediatricians’ preferences for speciﬁc features of hypothetical infant
meningococcal vaccines. Methods: A sample of pediatricians (n ¼
216) completed a Web-enabled, discrete choice experiment survey in
which respondents chose between pairs of hypothetical vaccines in a
series of trade-off questions. The questions described vaccines with
six attributes. A random-parameters logit regression model was used
to estimate the relative importance weights physicians place on
vaccine features. These weights were used to calculate the predictedee front matter Copyright & 2015, International S
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pondence to: Christine Poulos, RTI Health Solutioprobability that a physician chooses hypothetical vaccines with given
characteristics. Results: Pediatricians’ choices indicated that
increases in vaccine effectiveness were among the most important
factors in their vaccine recommendations, followed by increases in
the number of injections. The age at which protection begins and the
number of additional ofﬁce visits were less important. Whether a
booster was required after 5 years was the least important factor in
vaccine recommendations. The results suggest that virtually all
(99.9%) physicians in the sample would recommend a vaccine even
with the least-preferred features rather than no infant meningococcal
vaccine. Conclusions: Physicians’ responses indicate a strong prefer-
ence for infant meningococcal vaccination.
Keywords: conjoint analysis, discrete choice experiment, infant
vaccine, meningococcal disease, preference.
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Meningococcal disease is a rare infectious disease in the United
States, with 845 cases across all ages reported to the National
Notiﬁable Disease Surveillance System in 2010 [1,2]. Incidence is
highest among infants younger than 1 year (5.38 cases per
100,000) followed by adolescents (1.73 cases per 100,000) [1,3],
while the case-fatality rate is higher among adolescents (10%–
14%) than among infants (6%). Furthermore, 11% to 19% of the
survivors have permanent sequelae, such as hearing loss, neuro-
logic damage, or loss of a limb [1,4]. Because of the rapid
progression of the disease and its severe outcomes, meningococ-
cal disease can cause considerable anxiety among parents and
health care providers, and both sporadic cases and outbreaks can
place a signiﬁcant burden on health services (see, e.g., Krause
et al. [5] and Osterholm [6]).The Advisory Committee on Immunization Practices (ACIP)
recommends routine vaccination of 11- or 12-year-old children
with a quadrivalent meningococcal vaccine (serogroups A, C, Y,
and W-135) and a booster at 16 years. In recent years, the US Food
and Drug Administration (FDA) licensed two meningococcal
vaccines for use in infants, including a two-dose quadrivalent
meningococcal vaccine (serogroups A, C, Y, and W-135) for
administration beginning as early as age 9 months and a four-
dose bivalent combination vaccine (serogroups C and Y and
Haemophilus inﬂuenzae type b) for administration beginning as
early as age 6 weeks. As of October 2012, the ACIP recommended
that infants with certain risk factors for meningococcal disease
receive one of the licensed vaccines but did not endorse universal
infant vaccination [4,7]. The primary rationale for this decision
was based on the current epidemiology of meningococcal dis-
ease. Disease rates have declined in all age groups since 2000 andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Attributes and attribute levels used in
conjoint-analysis survey of physicians’ preference
for infant meningococcal disease vaccination.
Vaccine attribute Level
Age at which protection begins 4 mo
12 mo
2 y
Number of cases of disease,
disability, and death prevented
over 5 y
500 cases of disease,
125 cases of
disability, and 50
deaths prevented
425 cases of disease,
110 cases of
disability, and 43
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 768are at historically low levels, and more than one-half of the cases
in infants younger than 1 year are caused by serogroup B, which
is not prevented by any meningococcal vaccine licensed in the
United States [3,4]. In addition, published cost-effectiveness
analyses in the United States suggest that meningococcal vacci-
nation is not cost-effective [8–10].
Without a recommendation for universal vaccination, it is
unlikely that infant meningococcal vaccination will be covered by
the Vaccines for Children program or private health insurance
programs for children who are not at risk, though it will be
available to families who choose to use it (as well as to those with
children who are considered at risk). Thus, the use of infant
meningococcal vaccines will depend on physicians’ recommen-
dations to parents and parents’ willingness to vaccinate their
children. There is no quantitative evidence on parent or provider
preferences for meningococcal vaccines and vaccination strat-
egies in the United States.
This study aimed to quantify pediatricians’ preferences for
hypothetical meningococcal vaccines and vaccine features,
where ranges of vaccine features were selected to encompass
the features of currently available vaccines. The results will
indicate the importance that physicians place on infant menin-
gococcal vaccination. The study does not seek to rebut the results
of cost-effectiveness analysis. Rather, in contrast to the expert
opinion that informs vaccination licensure and recommendation
decisions by the FDA and the ACIP, provided by a limited number
of empaneled experts, this study quantiﬁes expert opinion using
a larger sample of physicians. This is the ﬁrst study of physician
preferences for meningococcal vaccines administered to this age
group and only the second study of preferences for meningococ-
cal vaccines in general. Bishai et al. [11] elicited parents’ prefer-
ences and willingness to pay for meningococcal vaccines for
adolescents. Similar methods have been used to quantify prefer-
ences for human papilloma virus vaccines in the United States
[12] and Vietnam [13] and for vaccines against cholera and
typhoid fever [14].deaths prevented
350 cases of disease, 88
cases of disability,
and 35 deaths
prevented
250 cases of disease, 63
cases of disability,
and 25 deaths
prevented
Number of injections added to the
schedule
0*
2
4
Number of additional doctor visits
required
0
1
3
Booster vaccine needed after 5 y Yes
No
Total out-of-pocket costs to
parents ($)
Narrower
cost
range
Wider
cost
range
0 0
10 25
25 75
75 150
* This represents a meningococcal vaccine administered as a
combination vaccine. Because a new combination vaccine may
replace one or more existing vaccines or vaccine series, it would
be possible for a new vaccine to both have no effect on the
number of injections in a particular child’s immunization sche-
dule and to require more doctor’s visits.Methods
Study Design
The methodological approach used was a discrete choice experi-
ment (DCE), or choice-format conjoint analysis, which is a valid
and reliable survey technique for eliciting trade-offs to quantify
the relative importance respondents assign to outcomes and
other features of health interventions [15–20]. DCE is based on
the premise that the attractiveness of an intervention is a
function of its attributes. In particular, the perceived value of
an intervention is a weighted sum of the attributes of the
intervention, where the weights reﬂect the sample’s average
perceived relative importance of each attribute. DCE questions
elicit preferences between pairs of hypothetical alternatives, and
statistical analysis of the pattern of these choices reveals the
relative importance weights respondents place on attributes.
The study followed best-practice guidelines as outlined in the
International Society for Pharmacoeconomics and Outcomes
Research checklist for conjoint-analysis applications in health
[16]. Vaccine attributes were selected to describe hypothetical
vaccines in the survey. The selection of attributes was informed
by the fact that current and possible future meningococcal
vaccines and vaccine strategies can vary in terms of the number
of cases prevented, the total number of injections children
receive, the additional number of visits to the physicians’ ofﬁces
for vaccination, and the total out-of-pocket costs of vaccines. In
addition, the research team, which included clinical experts who
reviewed study materials, conducted an informal review ofselected published and unpublished health economics, epidemi-
ology, and marketing studies related to infant meningococcal
vaccines. A list of possible vaccine attributes was discussed and
reﬁned by the study team. Attributes that remained on the list
were 1) relevant for deﬁning the clinical features of currently
available and potential vaccines; 2) reﬂected other, nonclinical
features of concern to physicians; and 3) incorporated physicians’
assessment of patient concerns. If the sources or discussions
concluded that an attribute did not meet these criteria or would
not distinguish among hypothetical meningococcal vaccines, it
was not included in the attribute list. The hypothetical vaccine
attributes were evaluated in face-to-face semi-structured inter-
views with 10 pediatricians in the United States.
The ﬁnal hypothetical vaccine attributes (Table 1) included
vaccine effectiveness (deﬁned in terms of the number of cases of
disease, disability, and death prevented over 5 years), age at
which protection begins, the number of injections added to the
immunization schedule, the number of additional doctors’ ofﬁce
visits required to administer the vaccine, whether a booster
Table 2 – Two risk-information formats.
Constant-base population information format
Out of 1 million children younger than 10 y:
 333 are hospitalized for head and neck injuries each year
 200 are diagnosed with acute appendicitis each year
 15 are diagnosed with acute myeloid leukemia (AML) each year
 11 are diagnosed with meningococcal disease each year (about
the same number die from drowning each year)
Variable-base population information format
 1 out of 3,000 children younger than 10 y is hospitalized for
head and neck injuries each year. That is about the same as
1 child in a town with 20,000 residents.
 1 out of 5,000 children younger than 10 y is diagnosed with
acute appendicitis each year. That is about the same as 1 child
in a town with 35,000 residents.
 1 out of 65,000 children younger than 10 y is diagnosed with
AML each year. That is about the same as 1 child in a city
with 450,000 residents, such as Albuquerque, NM; Kansas
City, MO; or Long Beach, CA.
 1 out of 90,000 children younger than 10 y is diagnosed with
meningococcal disease each year. That is about the same as
1 child in a city with 650,000 residents, such as Boston, MA;
Memphis, TN; or Baltimore, MD. (About the same number of
children younger than 10 y die from drowning each year.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 7 69vaccine would be required after 5 years, and total out-of-pocket
cost of vaccination for parents. The range of attribute levels was
selected using the following criteria: 1) it should span the
clinically relevant range of outcomes that has been observed or
is likely to be observed with currently available and candidate
vaccines; 2) it should span the changes in features likely to be
observed in practice; and 3) it should encompass the maximum
range over which respondents are willing to accept trade-offs
among attributes.
Many of the pediatricians interviewed noted that the cost to
parents is an important determinant of whether parents choose
to vaccinate and whether they choose to complete a vaccine
series. Physicians’ proxy assessments of the relative importance
of cost to parents, however, cannot be used to calculate welfare-
theoretic willingness to pay because physicians’ stated vaccine
recommendations are not subject to a binding budget constraint.
Nevertheless, physicians’ perceptions of the importance of costs
could be useful in evaluating vaccine policies. Because the costs
of many vaccines in the United States either are fully covered by
health insurance or are free, we evaluated physicians’ attentive-
ness to the hypothetical costs with a scope test of the internal
validity of respondents’ sensitivity to absolute differences in
costs [21]. The scope test consisted of randomly assigning
approximately one-half of respondents to a narrower range of
costs ($0–$75) and the other half to a wider range of costs
($0–$150).
Although vaccine safety is important to parents making
vaccine choices for their children [22], it was not included among
the attributes in the study. Rather, physician respondents were
told to assume that all the hypothetical vaccines described in the
survey had the same risk of mild side effects, such as injection-
site reactions. Respondents were also told that the hypothetical
vaccines described in the survey may be different than vaccines
that are currently available or in development.
Communicating both the baseline risks of meningococcal
disease and changes in that risk due to vaccination is challenging
because people often have difﬁculty evaluating such small
incidence rates. Among the errors people make when evaluating
risks are disregarding very small probabilities [23], misunder-
standing numerical measures of risk by paying more attention to
fraction numerators than denominators [24], or subjectively
editing small probabilities upward when outcomes are perceived
to be severe [25].
To facilitate the communication of meningococcal disease
risks and risk changes, risks were presented as frequencies,
which are easier to understand than are other statistical formats
[26]. The study also incorporated a risk-communication experi-
ment to evaluate whether denominator neglect [24]—a possible
bias in risk perception—inﬂuenced physicians’ preferences for
vaccine features. It is believed that respondents rely relatively
more on numerators when comparing different risks, leading to
misperceptions of risk. To test whether physician respondents
were susceptible to this bias, they were randomly assigned to one
of two formats for presenting information on the risk of menin-
gococcal disease (Table 2). The ﬁrst description expressed risks in
terms of the number of cases in a constant-base population
(constant-base population information format). The second
description expressed risks in terms of the size of the base
population in which one case would be realized (variable-base
population information format).
To create hypothetical vaccine proﬁles for the recommenda-
tion questions, we used an SAS implementation of a commonly
used algorithm to generate an unlabeled, D-efﬁcient, fractional
factorial experimental design that resulted in 36 hypothetical
vaccine pairs [27–30]. Because the quality of responses to choice
questions declines when the number of choice questions leads to
fatigue or cognitive burden [31–33], the 36 paired comparisons inthe experimental design were divided into four survey versions,
each containing nine choice questions. Each physician was
randomly assigned to one of the four versions and the order of
the choice questions was randomized for each respondent. If
physicians were assigned to the narrower cost range, the cost
levels shown in the choice questions corresponded to the levels
in the narrower range, and vice versa if physicians were assigned
to the wider cost range. The risk-communication format did not
affect the way information was presented in the choice questions
or the experimental design. In each choice question, physicians
were asked to indicate which of two hypothetical meningococcal
vaccine proﬁles they would recommend for addition to the
immunization schedule or whether they would not recommend
either of the two alternative vaccines (Fig. 1). The survey also
collected demographic information about the physicians.
Study Sample
Physicians were recruited from the Physicians Consulting Net-
work, a national online physician panel that veriﬁes members’
medical education with the American Medical Association. All
participating physicians were board-eligible or board-certiﬁed
pediatricians in the United States. The 20-minute online survey
was administered in August 2011. Respondents were given a $55
cash honorarium if they completed at least one choice question
in the survey. The Ofﬁce of Research Protection and Ethics at
Research Triangle Institute granted a consent exemption for
this study.
Model and Analysis
In each choice question, we assume that the provider chose the
vaccination (vaccine A, vaccine B, or neither) that provided the
most subjective value, which is a form of the standard random
utility model formulation [34]. In particular, we posit that the
provider i’s choice, vni,k, is the solution to the following:
Ui vkð Þ¼ max Ui¼ max
Ui,k AGEk,EFFk,INJk,VISk,BSTk,Pkð Þ
Ui,k¼0
(
ð1Þ
where vk is the provider’s choice; k denotes vaccine A, vaccine B,
or the opt-out choice (k ¼ 0); Ui,k is the perceived value of vaccine
Fig. 1 – Example choice question. Before seeing the choice questions, respondents were shown the following text: “In this
section, we will ask you to consider different possible meningococcal vaccines for infants. In each question, we will ask you to
choose the vaccine that you think should be added to the vaccine schedule. All of the vaccines provide 5 years of protection
from meningococcal disease and they all have the same, very low risk of side effects. They also have the same risk of mild
side effects (such as injection-site reaction). These vaccines may be different than vaccines that are currently available or in
development. Note that the addition of an infant meningococcal vaccine would not change the recommendation to vaccinate
adolescents against meningococcal disease. It also would not affect the availability of meningococcal vaccines currently used
to vaccinate adolescents and other individuals at risk of infection.”
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 770k to provider i, which depends on the vaccine characteristics,
including the age at which protection begins (AGE), the vaccine
effectiveness (EFF), the number of additional injections (INJ), the
number of additional ofﬁce visits (VIS), whether a booster vaccine
is required (BST), and the cost (P); and Ui,k¼0 is the perceived value
of no vaccination.
To estimate the model, we assume that the provider’s utility
is a separable and linear function of the health outcomes and
characteristics associated with each vaccine alternative, vk.
Equation 1 becomes
Ui vk¼A,B
 ¼βi,ageAGEkþβi,ef f tEFFkþβi,injINJkþβi,visVISk
þβi,bstBSTkþβi,λPk ð2Þ
Ui vk¼0ð Þ¼βi,optOPT ð3Þ
where OPT is an effects-coded variable equal to 1 if the provider
selected the opt-out alternative and equal to 1 otherwise.
The pattern of respondents’ responses to the choice questions
was analyzed using conditional logit and random-parameters
logit (RPL) models. As shown in Equations 2 and 3, the dependent
variable was discrete vaccine choice (or, recommendation), and
the explanatory variables included effects-coded categorical var-
iables describing the levels of the hypothetical vaccine attributes
associated with the vaccines presented in the recommendation
questions and an effects-coded variable indicating whether the
respondent would recommend “neither” vaccine. To examinewhether preferences for any vaccine features depended on the
levels of other vaccine features, we included interactions
between effects-coded variables. The i subscripts on the param-
eters measuring the marginal utility of the vaccine characteristics
(β) indicate that all variables had random parameters with
normal distributions in the RPL model. All analyses were con-
ducted using NLOGIT 4.0, and the RPL models used 500 draws
from the Halton sequence (Econometric Software, Inc.,
Plainview, NY).
The estimated parameters are log-odds preference estimates
for the hypothetical vaccine attributes relative to the mean effect,
normalized at zero. The estimates indicate the relative impor-
tance of each attribute level and can be interpreted in three ways
[35–37]. First, the vertical distance between the importance
weights for the best and worst levels of any attribute indicate
the overall importance of that attribute over the range of levels
included in the study relative to the importance of other attrib-
utes. Second, differences between adjacent importance weights
indicate the relative importance of moving from one level of an
attribute to an adjacent level of that attribute: the greater the
difference, the more important the change from one level to the
next. Third, the difference between adjacent importance weights
of one attribute can be compared directly with the difference
between adjacent importance weights of a different attribute.
The RPL parameter estimates were used to calculate both the
percentage of respondents who would choose a hypothetical
Table 3 – Sample characteristics.
Characteristic Frequency in sample
(percentage of sample)
Sex
Male 142 (65.7)
Female 74 (34.3)
Number of years in practice
o1 0
1–3 2 (0.9)
4–6 9 (4.2)
7–9 20 (9.3)
10–15 52 (24.1)
16–20 43 (19.9)
21–25 36 (16.7)
>25 54 (25.0)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 7 71infant meningococcal vaccine with given characteristics and the
minimum acceptable efﬁcacy (MAE). MAE is the smallest number
of meningococcal disease cases prevented over 5 years necessary
to compensate for an undesirable change in vaccine features.
Similar to the maximum acceptable risk [38], the MAE is calcu-
lated as the ratio of the relative importance of a worsening in
vaccine features divided by the relative importance of preventing
a case of a meningococcal disease (efﬁcacy).
The parameter estimates were combined with vaccine proﬁles
in the experimental design to obtain a weighted, mean-value
conjoint-utility index for the vaccine of interest. The conjoint-
utility index was used to examine how the likelihood that one
vaccine would be chosen over another vaccine (predicted choice
probability) would change in response to changes in a single
vaccine attribute, holding all other attributes constant as well as
the probability of choosing vaccines with given proﬁles as
a whole.Type of practice
Ofﬁce-based private practice 185 (85.6)
Hospital-based private practice 14 (6.5)
Academic hospital-based
practice
19 (8.8)
Other 8 (3.7)
Percentage of patients covered by*
Medicaid 30.5  25.7
Tricare insurance (for military
families)
4.8  8.1
Private insurance 59.2  27.4
No insurance 5.5  6.6
Treated a case of meningococcal
disease
181 (83.8)
Offer the quadrivalent
meningococcal conjugate
vaccine (MCV4) to adolescents
211 (97.7)Results
Physician Sample Characteristics
Eleven hundred board-certiﬁed or board-eligible pediatricians
were invited to participate. The e-mail invitation indicated that
the survey was about vaccinations. Two hundred sixteen (19.6%)
pediatricians agreed to participate (Table 3).
Two respondents always selected the same vaccine (either
vaccine A or vaccine B) in the recommendation questions. These
two respondents were deleted from the sample because this lack
of variation suggested that these respondents did not pay
attention to the recommendation questions. The ﬁnal sample
size used for analysis was 214.patients
* Values are mean  SD.
Preferences for Vaccine Attributes
Initially, we estimated separate conditional logit models for the
subsamples that saw the constant-base population risk-
information format (n ¼ 109) and the variable-base population
risk-information format (n ¼ 105) (see Table 4.) A Swait-Louviere
test [39] indicated that the estimated parameters from these two
models were quantitatively (and statistically) similar, meaning
that physician preferences for hypothetical vaccine attributes did
not vary with the risk-information format. The data from
respondents considering the two different risk-information for-
mats were pooled for the remaining analyses.
In addition, we estimated separate conditional logit models
for the subsamples that saw the narrower cost range (n ¼ 112)
and the wider cost range (n ¼ 102) (see Table 4). Figure 2
compares the importance weights for costs in these two sub-
samples. The distance between the best and worst levels of out-
of-pocket costs to parents for the narrower cost range was 1.4
(¼ 0.5 – [–0.9]); the distance between the best and worst levels of
out-of-pocket costs to parents for the much wider cost range was
1.7 (¼ 0.7 – [–1.0]). These relative differences are small compared
with the large numeric differences in the ranges, and a t test
indicated that they were not statistically different from one
another (P ¼ 0.05). The ﬁndings are consistent with respondents
recoding the levels of parental cost as, for example, “none,” “low,”
“medium,” and “high,” regardless of whether they were assigned
to the narrower or wider cost range, rather than paying attention
to the actual cost. These results suggest that the aggregate results
did not pass this internal validity test. Furthermore, a Swait-
Louviere test [39] indicated that the estimates were not statisti-
cally different in these two models. For all further analyses, we
pooled the data from respondents considering the narrower costrange with the data from respondents considering the wider
cost range.
An RPL model was estimated using the full data set. Table 5
and Figure 3 present the estimated log-odds preference estimates
and 95% conﬁdence intervals (CIs) for the ﬁve vaccine attributes
relative to the mean effect, normalized at zero. The estimates are
logically ordered. Respondents preferred protection at an earlier
age, higher vaccine effectiveness, fewer additional injections and
doctor’s visits, and the absence of a required booster.
The models in Table 5 also show that physicians’ preferences
for the meningococcal vaccine effectiveness and the number of
additional injections vary with the age at which protection
begins. In particular, physicians place a lower weight on the
highest level of protection (preventing 500 cases of disease) when
the vaccine provides protection to the youngest age group; they
place a higher weight on the same level of protection when the
vaccine provides protection at age 12 months; and they place a
higher weight on the three highest levels of protection when the
vaccine provides protection to the oldest age group (24 months).
In addition, physicians place a lower weight on the highest level
of additional injections when protection is provided to the
youngest age group and a higher weight on no additional
injections if protection is not provided until 24 months. The
statistically signiﬁcant estimates of SD in Table 5 indicate the
attribute levels for which there was heterogeneity in providers’
preferences.
Note that Figure 3 presents the weights for only those levels of
the age and visit attributes that correspond to features of actual
candidate meningococcal vaccines (age 4 and 12 months, and 0
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 7 73and 1 additional visit, respectively). The vertical distance
between importance weights indicates the relative importance
of moving from one level of an attribute to another level of that
attribute. For example, the relative importance of an improve-
ment in vaccine effectiveness that increases the number of cases
prevented from 250 to 350 was approximately 1.2 (¼ [–2.1] –
[–0.9]). The relative importance of a change in the age at which
protection begins from 4 to 12 months was approximately 0.7
(¼ 0.8  0.1). Therefore, an increase in the number of cases
prevented from 250 to 350 was approximately 1.7 times as
important as changing the age at which protection begins from
4 to 12 months. The same improvement in effectiveness was
approximately 1.1 times as important as increasing the number
of additional injections from 0 to 2 (1.1 ¼ 1.10 – [–0.02]) and 8.3
times as important as increasing the number of doctor visits by 1
(0.1 ¼ 0.5 – 0.4).
Given the attributes and levels used in the trade-off questions,
respondents placed the greatest importance on improving effec-
tiveness from preventing 250 cases to either 425 or 500 cases,
improving effectiveness from preventing 350 cases to 500 cases,
and increasing the number of additional injections required from
0 to 4. Respondents placed the smallest importance on the need
for a booster vaccine.
The large negative preference estimate for the effects-coded
opt-out variable indicates that respondents placed a very large
weight on having an infant meningococcal vaccine in the vaccine
schedule rather than not having one in the schedule. Most
respondents (n ¼ 171 or 79.9%) never selected the “no vaccine”
option in the recommendation questions. Of the 1926 recom-
mendation questions in the study, the no vaccine option was
selected in 120 questions (6.2%). The results suggest that nearly
all (99.96%; 95% CI 97%–100%) physicians in the sample would
choose a vaccine with even the least-preferred vaccine features
(i.e., protection begins at 12 months; 250 cases of disease, 63 cases
of disability, and 25 deaths prevented; four injections added to
the immunization schedule; one additional doctor’s visit
required; no booster required; and an out-of-pocket cost of $150
to parents) rather than choose no infant meningococcal vaccine.
We estimated two additional models: 1) a main effects only
RPL model and 2) an RPL model with the speciﬁcation shown in
Table 5 but estimated using 1000 Halton draws. The former
results (not shown) indicated that the parameter estimates from
the main effects only model were not statistically different from
the main effects shown in Table 5. Furthermore, the parameter
estimates based on the model using 1000 Halton draws (not
shown) were not statistically different from the RPL parameters
based on 500 Halton draws.
Table 6 presents selected MAE results. For example, to accept
an increase in the age at which protection begins from 4 months
to 12 months, respondents would require that the vaccine
prevent an additional 31 cases of meningococcal disease over 5
years (95% CI 6.6–55.4). Respondents would require that more
than three times as many additional cases of meningococcal
disease be prevented over 5 years (100.7 cases; 95% CI 47.2–154.2)
to accept an increase in additional injections from zero to four.
Given that more than one-half of respondents had at least 16
years of experience, we estimated separate conditional logit
models for the two subsamples composed of respondents with
at least 16 years of experience and less than 16 years of
experience to examine whether physicians with more experience
had preferences different from those of the remaining physi-
cians. A Swait-Louviere test [39] indicated that the relative scale
of the two models was different (estimated relative scale factor ¼
1.17; 95% CI 1.02–1.33). After accounting for the difference in
scale, a likelihood-ratio test indicated that the preference weight
estimates were not statistically different in these two groups
(likelihood-ratio test statistic ¼ 21.27; P ¼ 0.68).
Fig. 2 – Estimated physicians’ preference weights for total out-of-pocket costs, by cost range. Respondents were randomly
assigned to one of the two cost ranges. The levels for parental costs in the narrow cost range were $0, $10, $25, and $75. The
levels for parental costs in the wide cost range were $0, $25, $75, and $150.
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In view of the fact that the ACIP has not endorsed universal
infant meningococcal vaccination and it is unlikely that the
Vaccines for Children program or private health insurance pro-
grams will cover the vaccine for children who are not at risk of
meningococcal disease, the use of infant meningococcal vaccine
by these families will depend on physicians’ and parents’ pref-
erences for infant meningococcal vaccination. To our knowledge,
these results provide the ﬁrst systematic quantiﬁcation of US
pediatricians’ subjective evaluation of the desirability of vacci-
nating infants up to age 12 months against meningococcal
disease. When making decisions about licensing vaccines and
recommending their use, the FDA’s and ACIP’s decisions are
informed by the expert opinions of a limited number of empan-
eled physicians. In this study, we have surveyed a larger number
of physicians and found that pediatricians place great impor-
tance on the vaccination of infants against meningococcal dis-
ease. Although this study does not rebut the cost-effectiveness
ﬁndings with respect to infant meningococcal vaccination, it
indicates the importance that pediatricians place on these vac-
cinations. Respondents’ strong preference for adding a meningo-
coccal vaccine for infants is reﬂected in the result that virtually
all the physicians in the sample would choose a vaccine even if it
had the least-preferred vaccine features rather than choose no
infant meningococcal vaccine. Although our study did not
directly address the difference between universal and permissive
recommendations, the vaccine recommendation question asked
physicians which vaccine they would recommend adding to the
immunization schedule. Participants in the pretest understood
that the hypothetical vaccine would be recommended for all
children.
Second, the study indicates that pediatricians thought that
some of the increases in vaccine effectiveness were among the
most important factors in their vaccine recommendations, fol-
lowed by some of the increases in the number of injections.Whether a booster was required after 5 years was the least
important factor in vaccine recommendations. The results show
that physicians reacted logically to higher prices (preference
weights declined as cost increased), but they generally were
insensitive to the absolute level of prices parents would have to
pay. Third, the MAE estimates implied that vaccines that require
additional injections would require a larger increase in efﬁcacy to
offset the undesirable change that would be required to compen-
sate for changes in age at which protection begins or the number
of additional ofﬁce visits.
Although there have been no previous studies of physicians’
preferences for meningococcal vaccines, health care providers
participated in four public Centers for Disease Control and
Prevention (CDC) meetings discussing the vaccination of infants
and toddlers against meningococcal disease [40]. The DCE study
results reported in this article provide quantitative evidence to
support the qualitative data on provider attitudes reported by the
CDC. For example, Nowak [40] reported that some health care
providers attending the CDC-sponsored public meetings were
concerned about adding vaccines to an already crowded vaccine
schedule [40]. This is reﬂected in the fact that the second most
important vaccine attribute in this study was the number of
vaccines added to the immunization schedule. Furthermore, the
results reported in this article are similar to the results of an
unpublished survey of health care providers [40] that indicated
that 90% of the providers would recommend infant meningococ-
cal vaccination to parents if the ACIP endorsed universal immu-
nization and there were no additional injections required. The
results also indicated that providers’ willingness to recommend
the vaccine to parents would decline if the ACIP did not endorse
universal immunization, or the number of injections increases, or
a vaccine would require a change in the use of other vaccine
products. Although the DCE study asked about physicians’ will-
ingness to recommend adding a vaccine to the immunization
schedule, rather than their willingness to recommend a vaccine
to parents, the DCE study results are qualitatively similar to the
results of the unpublished physician survey [41]. Both our study
Table 5
A B K L M
Attribute Level RP Logit
β SE SD
Age at which protection begins (months) 4 0.76*** 0.15 1.56***
12 0.09 0.11 0.56***
24 -0.84*** 0.17 Omitted
Number of cases of disease / disability / death
prevented over ﬁve years
500/125/150 2.12*** 0.33 1.51***
425/110/43 0.91*** 0.18 0.08
350/88/35 -0.91*** 0.18 0.23
250/63/25 -2.12*** 0.34 omitted
Number of injections added to the schedule 0 1.10*** 0.18 0.55***
2 -0.02 0.13 0.18
4 -1.08*** 0.17 omitted
Number of additional visits required 0 0.52*** 0.15 0.70***
1 0.38** 0.16 0.37**
3 -0.90*** 0.18 Omitted
Need a booster vaccine after 5 years Yes -0.26*** 0.09 0.20
No 0.26*** 0.08 Omitted
Total out-of-pocket-cost to parents (for all vaccine
doses)
$0 1.79*** 0.30 1.71***
$10 or $25 1.16*** 0.25 1.54***
$25 or $75 -0.01 0.16 0.79***
$75 or $150 -2.94*** 0.47 Omitted
Interaction between protection at 4 mos and no. of
cases prevented
4 mos X 500/125/150 -0.76** 0.30 1.36***
4 mos X 425/110/43 -0.01 0.30 0.82***
4 mos X 350/88/35 0.41 0.30 0.45
4 mos X 250/63/25 0.22 0.19 Omitted
Interaction between protection at 12 mos and no.
of cases prevented
12 mos X 500/125/150 0.64** 0.31 0.83***
12 mos X 425/110/43 -0.25 0.31 0.57**
12 mos X 350/88/35 -0.35 0.27 0.56
12 mos X 250/63/25 -0.04 0.36 Omitted
Interaction between protection at 24 mos and no.
of cases prevented
24 mos X 500/125/150 0.12*** 0.34 Omitted
24 mos X 425/110/43 0.26*** 0.26 Omitted
24 mos X 350/88/35 -0.06*** 0.32 Omitted
24 mos X 250/63/25 -0.32 0.32 Omitted
Interaction between protection at 4 mos and
additional injections
4 mos X 0 additional injections -0.17 0.24 0.37
4 mos X 2 additional injections 0.49** 0.22 0.73**
4 mos X 4 additional injections -0.32 0.23 Omitted
Interaction between protection at 12 mos and
additional injections
12 mos X 0 additional injections 0.09 0.27 0.03
12 mos X 2 additional injections -0.24 0.26 1.30***
12 mos X 4 additional injections 0.15 0.28 Omitted
Interaction between protection at 24 mos and
additional injections
24 mos X 0 additional injections 0.07*** 0.24 Omitted
24 mos X 2 additional injections -0.25 0.26 Omitted
24 mos X 4 additional injections 0.18 0.27 Omitted
Opt-out Opt-out -7.53*** 1.30 5.44***
Swait-Louviere Test Results Estimated relative scale factor (95% conﬁdence
interval)
N/A
Likelihood ratio statistic for joint test of parameter
equivalence (p-value)
N/A
β ¼ mean parameter estimates, or mean preference weight estimates; SE¼standard error of parameter estimate; SD¼Standard deviation of
mean parameter. This is an estimate of the variability of or heterogeneity in the parameter estimate; N/A¼not applicable
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 7 75and the unpublished physician survey [41] indicate strong sup-
port for vaccination despite the low incidence of the disease and
the fact that infant meningococcal vaccination is not cost-
effective. It is not clear from either study why physicians place
such importance on infant meningococcal vaccination, but sev-
eral pretest respondents in the present study stated that they are
very concerned about misdiagnosing the disease or otherwise
having their patients experience severe meningococcal disease
outcomes. These concerns may cause respondents to inﬂate the
small disease risks. The only previous study of preferences for
meningococcal vaccination was undertaken by Bishai et al. [11].The study elicited German and French parents’ preferences and
willingness to pay for adolescent meningococcal vaccines. As in
our study, most respondents in the Bishai et al. [11] study (93%)
indicated that they would purchase a vaccine if it was not free.
The study results indicated that the uptake of a quadrivalent
meningococcal vaccine that lasted 10 years would be 50% in
France and Germany at prices of €80 and €50, respectively.
Our risk-communication experiment found that preferences
for infant meningococcal vaccines did not vary with different
risk-information formats. This result contrasts with previous
ﬁndings for nonphysicians that people often focus on fraction
Fig. 3 – Physician preference weights for features of infant meningococcal vaccines, parameter log odds relative to mean effect.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 776numerators and pay less attention to denominators in probability
assessments [2]. Experts may make fewer errors in decision
making if their processing of risk information improves as
expertise develops [42].
Despite the increasing use of DCE in health applications to
elicit preferences [15,43,44], this approach has several potential
limitations. One inherent limitation is that the physicians eval-
uated hypothetical vaccine proﬁles that do not have the same
signiﬁcance as recommendations involving actual vaccines. We
minimized the potential for hypothetical bias by offering vac-
cines that mimic real-world trade-offs as closely as possible.
Furthermore, physicians’ actual vaccine choices may differ fromTable 6 – Minimum acceptable efﬁcacy (additional cases
exchange for changes in vaccine features.
Change in Vaccine Features
Increasing the age at which protection
begins from 4 to 12 months
Increasing the number of additional
injections required from
0 to 4 injections
2 to 4 injections
0 to 2 injections
Increasing the number additional doctor’s
visits from 0 to 1 visit
Changing requirement for booster from no booster to
booster required after 5 yearspredicted choices because actual choices depend on a number of
clinical, institutional, and ﬁnancial factors that are beyond the
scope of this study. One of the key issues in the real-world policy
discussion about infant meningococcal vaccines is the breadth of
protection provided by available vaccines. Our study did not
disclose whether the hypothetical vaccines were bivalent or
quadrivalent. Rather, it presented hypothetical effectiveness
levels that varied over a range consistent with protection against
different serogroups. Given the estimated annual burden of
disease reported in Cohn et al. [3], the range of vaccine effective-
ness shown in the DCE study (described in terms of the number
of cases prevented over 5 years) would be approximatelyof meningococcal disease prevented over 5 years) in
Mean Minimum
Acceptable Efﬁcacy
95% Conﬁdence
Interval
31 7- 55
101 47-154
49 17-81
52 19-85
7 12-25
24 3-46
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 7 – 7 7 77equivalent to bivalent and quadrivalent infant meningococcal
vaccines that would be approximately 33% to 66% and 25% to 50%
effective, respectively. Also, although vaccine safety was not
included as an attribute because there have been no signiﬁcant
safety problems associated with meningococcal vaccines,
respondents were asked to assume that all the hypothetical
vaccines described in the survey had the same risk of mild side
effects, such as injection-site reactions.
Furthermore, as in any survey-research study, we need to be
mindful of sample representativeness as a potential study limi-
tation. Although the sampling procedure was not inherently
biased, the sample was small relative to the population. We
cannot fully judge how representative our pediatrician sample
was or whether our results are generalizable to all US
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